RxDoctor Payments Data

Ivan Rodriguez, DO

Family Medicine · Hialeah, FLNPI 1649292012

Payments from drug & device makers

$41,108in general payments, 2019–2025

Across 79 payments — averaging $520.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Convatec Inc.$38K
  • Sunovion Pharmaceuticals Inc.$972
  • Neurocrine Biosciences, Inc.$755
  • Acadia Pharmaceuticals Inc$607
  • Teva Pharmaceuticals USA, Inc.$405
  • Viiv Healthcare Company$144
  • plus $425 from 9 others

What the payments were for

  • Food & beverage$3,3088%
  • Other$37,80092%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$41,108 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$809,911
Medicare patients
361
Services billed
7,547

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate96$573,046
NuplazidPimavanserin Tartrate58$178,153
EliquisApixaban429$146,945
EnbrelEtanercept22$54,722
GenvoyaElviteg/Cob/Emtri/Tenof Alafen13$49,481
TrulicityDulaglutide74$45,339
NuedextaDextromethorphan Hbr/Quinidine59$38,566
Invega SustennaPaliperidone Palmitate11$35,927
XareltoRivaroxaban101$32,753
OzempicSemaglutide28$26,787
EntrestoSacubitril/Valsartan81$26,385
JanuviaSitagliptin Phosphate49$22,945
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$21,202
JardianceEmpagliflozin51$19,387
FarxigaDapagliflozin Propanediol46$19,007

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$755$573,04696 claims
Acadia Pharmaceuticals IncNuplazid$607$178,15358 claims
PfizerEliquis$49$146,945429 claims
GileadGenvoya$33$49,48113 claims
Lilly USA, LLCTrulicity$34$45,33974 claims
Avanir Pharmaceuticals, Inc.Nuedexta$24$38,56659 claims
MerckJanuvia$91$22,94549 claims
Sunovion Pharmaceuticals Inc.Aptiom$972$13,28821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Hialeah

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →